BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38309725)

  • 1. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
    Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
    Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
    Wei B; Kang J; Kibukawa M; Arreaza G; Maguire M; Chen L; Qiu P; Lang L; Aurora-Garg D; Cristescu R; Levitan D
    J Mol Diagn; 2022 Jun; 24(6):600-608. PubMed ID: 35218944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
    Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
    Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
    Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
    J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
    Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    Stenzinger A; Endris V; Budczies J; Merkelbach-Bruse S; Kazdal D; Dietmaier W; Pfarr N; Siebolts U; Hummel M; Herold S; Andreas J; Zoche M; Tögel L; Rempel E; Maas J; Merino D; Stewart M; Zaoui K; Schlesner M; Glimm H; Fröhling S; Allen J; Horst D; Baretton G; Wickenhauser C; Tiemann M; Evert M; Moch H; Kirchner T; Büttner R; Schirmacher P; Jung A; Haller F; Weichert W; Dietel M
    J Thorac Oncol; 2020 Jul; 15(7):1177-1189. PubMed ID: 32119917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
    Jung J; Heo YJ; Park S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
    Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
    Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
    Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
    Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.